CD19 CAR T-cell therapy is the focus of a clinical report that readers can open to learn about a novel immunotherapy approach for severe rheumatoid arthritis and its potential to reset autoimmune responses.
Key Takeaways
- Six people with refractory seropositive rheumatoid arthritis received CD19 CAR T-cell therapy in a phase 1 trial
- Three participants achieved medication-free clinical remission after treatment
- Authors propose the therapy clears pathogenic B cells and reboots immune regulation, but larger trials are needed